ABSTRACT. Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates a spectrum of toxic and biological effects of 2,3,7,8-tetrachloro dibenzo-p-dioxin (TCDD) and related compounds. Peroxisome proliferator activated receptor alpha (PPARα) is a nuclear receptor involved in the maintenance of lipid and glucose homeostasis. In this study we hypothesized that one of the possible mechanisms for the effect of TCDD and its related chemicals on fat metabolism could be through down regulation of PPARα functions. We treated Wistar rats with an AhR ligand, Sudan III (S.III), and/or PPARα ligand, Clofibric Acid (CA), for 3 days. We analysed the expression of one of the PPARα-target gene products, CYP4A protein and its mRNA. We also tested HepG2 cells with the afore-mentioned treatments and evaluated their effects on PPAR α and RXRα protein. Treatment of Wistar rats with S.III was found to down regulates CYP4A protein expression and reduced its induction with CA. It also decreased mRNA expressions of CYP4A1, CYP4A2, CYP4A3 and PPARα. In HepG2 cells, PPARα and RXRα protein expression was decreased by S.III treatment in a dose dependent manner. Our results suggest that AhR has an inhibitory effect on PPAR α function and a new pathway by which AhR ligands could disturb lipid metabolism. KEY WORDS: AhR, CYP4A, PPARα rat, RXRα.
Peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor deeply involved in the maintenance of lipid and glucose homeostasis [39] and is mainly expressed in liver, muscle and heart [3, 40] . Activation of PPARα in liver, muscle and heart increases the expression and activity of lipoprotein lipase (LPL), an enzyme involved in lipolysis [35] , and therefore increases the clearance of TG-rich lipoproteins, and circulating TG levels. PPARα agonist, fibrates, inhibits ApoCIII, which act as a natural inhibitor of LPL activity [5] . Treatment of diabetic db/db mice with a PPARα agonist normalizes circulating free fatty acids,TG, and glucose levels [2] . Moreover PPARα influences the expression of numerous genes implicated in major pathways of amino acid metabolism, and fasting PPARα-null mice have higher plasma urea concentration compared to wild type [19] PPARα agonists, fibrates, have been in use for over 40 years for the treatment of dyslipidemia, mainly due to their actions of lowering TG levels, raising HDL [9] , and decreasing levels of LDL [40] . The CYP4A sub-family members which have a role in fatty acid and prostaglandin hydroxylation, are abundantly expressed in the liver and kidney [38] . The members of this sub-family are well known to be regulated by PPARα, which binds with RXRα to form heterodimers. These hetero-dimers then bind to enhancer elements PPRE on responsive genes including CYP4A family [17] . 20-hydroxyeicosatetraenoic acid is a major arachidonic acid metabolite of CYP4A isoforms in the microvasculature of the rat kidney and acts as a potent vasoconstrictor and mediator of the myogenic response [24] . Collectively, PPARα has an important role in lipid, glucose, and protein metabolism.
Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates a spectrum of toxic and biological effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds [37] . A hallmark of TCDD systemic toxicity involves an overall perturbation of energy homeostasis [31] . In rodents, low doses of TCDD result in diabetogenic effects, such as decreased glucose uptake, increased circulating triglycerides and insulin [34] and an overall loss of body fat and weight [25] . In a group of former TCDD workers, exposure to TCDD caused hyperlipidaemia, atherosclerotic plaques, ischaemic heart disease and neuropsychological disturbance, and a high percentage of them had elevated levels of triglycerides and/or cholesterol [29] . There are several lines of evidence suggesting the AhR as a negative regulator of adipocyte differentiation [1] . TCDD treatment prevented the increase of PPAR gamma expression in differentiating adipocytes [45] . Experimental animal exposure to TCDD, results in decreased levels of the glucose transporter (GLUT4) and reduced expression of many other adipocyte markers [22] . Recently, both cholesterol and triglycerides were reported to be increased shortly after intoxication with TCDD in two young women with extremely high blood TCDD levels [13] . Hyperlipidaemia is a well known predisposing factor for the development of Type 2 diabetes. A correlation between TCDD exposure and the development of type II diabetes mellitus has been suggested to be through opposition of PPARs mainly PPAR gamma [33] , but to date there is no information regarding the effect of AhR activation on PPARα expression and function. In the present study we investigated the effect of AhR ligand S.III on the expression of PPARα, its partner RXRα and their target genes CYP4A. Our results show that AhR stimulation causes down regulation of PPARα, RXRα, CYP4A protein and the mRNA expression of CYP4A1, CYP4A2, and CYP4A3, and suggest a role mediated by AhR in the down regulation of PPAR α function.
MATERIAL AND METHODS

Ainimal and treatments:
All experiments using animals were performed under the supervision and approval of the Institutional Animal Care and Use Committee. Nine-week old Wistar rats (SLC., Hamamatsu , Japan) were divided into 4 groups of 4 rats each, housed at 24 ± 1°C with 12 hr light and 12 hr dark cycle, and given laboratory feed and water ad libitum. Rats were treated with either 80 mg/kg S.III (Sigma Chemical Co., St. Louis, MO, U.S.A.), 80 mg/ kg S. III +300 mg/kg CA (Pfaltz & Bauer, Inc., NY, U.S.A.), 300 mg/kg CA, or vehicle, orally for 3 consecutive days. Twenty-four hours after the last dose, rats were sacrificed with carbon dioxide and livers were collected. The microsomal fractions from livers were prepared according to the method of Omura and Sato [28] , with slight modifications. Livers were minced and homogenized in 3 volumes of ice-cold 1.15% potassium chloride solution using a Teflon homogenizer. Homogenized samples were centrifuged at 9,000 × g at 4°C for 20 min. The supernatant fraction was centrifuged at 105,000 × g at 4°C for 70 min to obtain a mitochondria-free microsomal pellet. The washed microsomes were then suspended in 0.1 M potassium phosphate buffer (KPB), pH 7.4 and divided into 1.5 ml tubes and snapped in liquid nitrogen and kept at -80°C until use. Microsomal protein concentrations were determined according the method of Lowry et al. [23] using BSA (Sigma Chemical Co., St. Louis, MO, U.S.A.) as a standard.
Treatment of human hepatocarcinoma HepG2 cells: HepG2 cells, obtained from the American Type Culture Collection (Manassas, VA), were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin) at 37°C in a humidified incubator with 5% CO 2 in air. Cells were seeded in 60 mm collagen coated dishes and sub-cultured twice a week. HepG2 cells were grown to 80-90% confluence on 60 mm collagen-coated dishes. Full-length human PPARα from human liver cDNA libraries (BD Biosciences Co., MA, U.S.A.) was amplified by polymerase chain reaction (PCR) and subcloned into pDEST12.2 mammalian expression vector using the Gateway system (Invitrogen, CA., U.S.A.). HepG2 Cells were transfected with the pDEST-h PPARα full-length hPPAR α expression vector and/or the empty pDEST vector for equalization of the DNA amount, at concentration 1 µg/ml by using Trans-It (Mirus, Madison, U.S.A.) according to the instruction manual. Twenty-four hours later, cells were treated with either 0.1% DMSO (control), 500 µM CA or various concentrations of 0.01 to 10 µM S.III + 500 µM CA for a further 24 hr after which cells were scraped in ice-cold lysis buffer. The harvested cells were incubated on ice for 30 min, and the cell lysates were used as a whole for receptor measurement.
Western blot analysis: Aliquots of 12 µg of rat liver microsomal protein from treated and control rats, or of 100 µg of whole cell lysate were applied on 10-12% sodium dodecylsulfate (SDS) polyacrylamide gels and separated by electrophoresis as described by Laemmli [21] using a protean 2 mini 1-D cell (Bio Rad, Netherlands ). Western blot analysis was performed according to Towbin [44] . The proteins were electrophoretically transferred to nitrocellulose membranes, blocked in 5% skim milk in phosphate suffer saline (PBS) containing 1% tween 20 for 2 hr in case of rat liver microsomal samples and for 6 hr in case of HepG2 cell lysate samples at room temperature, and probed with the polyclonal goat anti-rat CYP4A1 (Daiichi Pure Chemical Co., Ltd., Tokyo, Japan), or rabbit-anti-human PPARα or RXRα or goat anti-human β-actin Santa Cruz Biotechnology, CA., U.S.A.) as solutions in PBS containing 1% Tween 20 on shaker for 2 hr at room temperature. Horseradish peroxidase-labeled rabbit anti-goat IgG (Sigma Chemical Co., St .Louis, MO, U.S.A.), or goat anti-rabbit (Santa Cruz Biotechnology, CA, U.S.A.) was used as secondary antibody. Immunoreactive protein bands were revealed colorimetrically either by oxidation of 0.025% 3,3 diaminobenzidine tetrahydrochloride (Kanto Chemical Co., Tokyo, Japan), with 0.0075% hydrogen peroxide and catalyzed by peroxidase in 50 mM Tris-HCL (pH 7.6), or by detection with a chemiluminscence Kit ECL-Plus (Amersham Life Science, Cleveland, OH, U.S.A.),with the use of Polaroid Camera. Intensities of the immunoreactive bands were densitometrically analysed using the Public domain NIH Image program (National Institutes of Health, MD, U.S.A.), available on the internet at (http://rbs.info.nih.gov/nih-image/).
Semi-quantitative RT-PCR: Total RNA was isolated from 50 mg of liver samples using TRIzol reagent (Life Technologies Inc, Grand Island, NY, U.S.A.), and dissolved in Diethyl pyrocarbonate (DEPC) water. cDNA was synthesized as follows: A mixture of 5 µg of total RNA and 0.5 ng oligo dT primer in a total volume of 24 µl sterilized ultrapure water, was incubated at 70°C for 10 min. It was then made up to 40 µl with a mixture of 8 µl (5X) RT-buffer, 2 µl 2.5 mM dNTP, 2 µl DEPC water, and 2 µl of reverse transcriptase (Toyobo Co., Ltd., Osaka, Japan). The incubation was done in the thermal cycler at 30°C for 10 min, 42°C forcycles for each gene using a DNA thermal cycler (Bio Rad, Hercules, CA, U.S.A.). The samples were finally incubated for 7 min at 72°C after the last cycle of amplification. The amplified PCR products were separated by electrophoresis through 1-2% agarose gel. Bands of DNA were stained with ethidium bromide and visualized by ultraviolet illumination. Intensities of the amplified DNA bands were densitometrically analyzed using the public domain NIH Image program. The primer sequences for CYP4A isoforms mRNA amplification were according to Wang et al. [46] . The primer sequences for rat PPARα mRNA amplification were constructed from rat PPARα gene sequence available in the Gene-Bank at accession number NM_013196, forward primer from 367-388: AACCATTCAACATGGTG-G ACA an d the re ve rse prim er fro m 1 78 1-18 0 1: GTACATGTCTCTGTAGATCT. The primer sequences for rat β-actin mRNA amplification were constructed from rat β-actin gene sequence available in the Gene-Bank at accession number V01217, Forward primer from 475-494: ATGTACGTAGC-CATCCAGGC,
Reverse primer from 1083-1102: TCCACACAGAG-TACTTGCGC.
Statistical analysis: All data were expressed as means ± SD. Statistical significances were evaluated using the Fisher's protected least significant difference test. An unpaired t -test was used to evaluate the comparisons between two means of two groups. P value less than 0.05 were considered to be statistically significant.
RESULTS
Down regulation of CYP4A by S.III treatment in rat liver: To investigate the effect of AhR activation on the PPARα activity, Wistar rat were treated with S.III as an AhR ligand and CA as a PPARα ligand. The PPARα target gene CYP4A protein, was measured in liver microsomes by Western blotting. Rats treated with S.III showed a significant reduction of CYP4A protein compared to control (Fig.  1A and B) . Treatment of rat with CA induced CYP4A protein six fold higher than control, while S.III co-treatment with CA, resulted in the reduction of CYP4A to only four and three fold depending on the dose of S.III treatment (Fig.  1C and D) , indicting that S.III inhibit the ability of CA to induce CYP4A.
To explore the level at which AhR-activation causes down regulation of CYP4A, we measured the mRNA expression of CYP4A isoforms in all groups of rats. The increase of CYP4A isoforms mRNAs were increased linearly with the increase of the cycle number, we choose the lowest cycle number that shows clearly the difference between the different treated groups. As expected CYP4A1 mRNA was induced more than 7 fold with CA as compared with control, and was reduced with S.III to 50% of control, while S.III co treatment with CA reduced CYP4A1 mRNA to only 60% of the CA-induced levels. CYP4A3 mRNA follows the same trend of CYP4A1 mRNA. It was induced 4 fold with CA treatment compared to control, reduced with S.III treatment relative to control, and reduced by S.III cotreatment with CA compared to CA alone. However both the induction with CA and the reduction with S.III treatment were not so high as in the case of CYP4A1 mRNA. It is worth noting that while S.III produced reduction of CYP4A1 and CYP4A3 mRNA compared to control, it unexpectedly increased CYP4A2 mRNA higher than control levels and CYP4A2 was also induced with CA treatment to 4-fold higher than control. S.III co-treatment with CA completely abolished the induction of CYP4A2 by CA (Fig. 2 A and B) . These results collectively show that AhR activation has an inhibitory effect on PPARα function manifested by down regulation of its target genes CYP4A mRNA and protein.
Effect of AhR activation on PPAR alpha and RXR alpha protein expressions: To further investigate the nature of the inhibitory effect of AhR activation on PPARα function, we examined the effect of AhR ligand on PPARα and its necessary partner RXRα protein expression in a human model HepG2 cells. Transfection of HepG2 with 0.5 µg/ml of hPPAR full-length PPARα expressing vector increased the PPARα expression to a highly detectable level compared to non-detectable in the non-transfected HepG2 cells. On the other hand treatment with 0.2 µM S.III reduced the expression of the transfected PPARα to less than 60% of the transfected control cells (Fig. 3 A and B) . We further exposed other sets of PPARα-transfected cells to increasing doses of S.III at concentrations from 0.01 to10 µM, which produced dose dependent decrease of PPARα protein expression (Fig.  4 A and B) . Treatment of the cells with S.III in the presence of CA also produced reduction of the receptor expression but not as much as S.III treatment alone (Fig. 4 C and D) .
We also investigated the effect of AhR ligand on the important PPARα-partner RXRα Treatment of HepG2 cells with S.III showed reduction of protein expression of RXR α in S.III dose-dependent manner (Fig. 5 A and B) . Since it was reported that PPARα ligand stabilizes RXRα so we treated HepG2 with CA which showed no induction of its protein expression, and S.III co treatment with CA produced the same effect of dose dependent-reduction of RXRα protein expression (Fig. 5 C and D) . To make sure of the level at which AhR stimulation affects on PPARα we measured the PPARα mRNA expression by semi-quantitative RT-PCR in different treated and control groups of rats. Treatment of rats with CA increased PPARα mRNA expression compared to control, and treatment with S.III decreased its expression compared to control, while S.III co-treatment decreased the CA-induced PPARα mRNA (Fig. 6A and B) . Moreover we measured RXRα mRNA also by the above method but we found no dramatic effects of either CA and/or S.III on RXRα mRNA expression (data not shown).
DISCUSSION
TCDD and dioxin-like chemicals are widespread and per-sistent in the environment. In rodents, low doses of TCDD resulted in diabetogenic effects, such as decreased glucose uptake, increased circulating triglycerides and insulin [34] and an overall loss of body fat and weight [25] . The toxic and biological effects of TCDD and related compounds are suggested to be mediated by a ligand-activated transcription factor AhR [37] since AhR-knock out mice were reported to be resistant to TCDD-induced toxicity [10] . A large body of evidence has clearly shown that AhR plays a role in the negative regulation of adipose differentiation in 3T3-L1 cells and has a negative regulatory effect on PPAR gamma expression and function [37] . CYP4A, enzymes, the regulation of which are mediated by PPARα act as fatty acid and prostaglandin hydroxylases that are abundantly expressed in the liver and kidney [42] . They have been reported to metabolize arachidonic acids to 20-hydroxyeicosatetraeinoic acid (20-HETE), a metabolite that has been implicated in diverse biological functions, including the regulation of vascular tone and renal tubular ion transport [32] . In this study we aimed to explore the effect of AhR on PPARα function. S.III is an AhR ligand that has been reported to have affinity to AhR and is a CYP1A inducer [14] . Treatment of Wistar rats with S.III induced the AhR target genes CYP1A1/ CYP1A2 mRNA, protein and their metabolic activities EROD and MROD [36] as an indication for the activation of AhR.
The down regulation of CYP4A protein expression with S.III treatment of Wistar rats (Fig.1A and B) indicates that AhR activation has an inhibitory effect on PPARα function. Moreover, the ability of AhR activation to decrease CYP4A induction with the PPARα ligand CA when S.III was cotreated with CA ( Fig. 1 D and C) confirmed the inhibitory effect of AhR on CYP4A. Furthermore, the reduction of the basal and the CA-induced expression of the mRNA of CYP4A1, and CYP4A3 with S.III treatment either alone or with CA (Fig. 2) suggests that AhR stimulation interferes with the transcription of all CYP4A isoforms. The induction of CYP4A2 mRNA with S.III (Fig. 2) would indicate the ability of AhR to stimulate some peroxisomal enzymes. Indeed, it was reported that TCDD and benz (a) anthracene (BA) stimulate the activities and increased the apoprotein levels of two peroxisomal enzymes, namely, acyl CoA oxidase and acyl CoA hydrolase, in intact C3H10T1/2 cells. This suggests a possible peroxisomal stimulatory effect of TCCD and BA [16] . However, the suppression of CYP4A2 induction in case of co-treatment with the PPARα and AhR ligand (Fig. 2 ) strengthen our proposed hypothesis that there is antagonistic cross-talk between the two receptors. This needs further investigation. The difference in the mode of regulation of CYP4A2 from that of CYP4A1 and CYP4A3 is well documented. CYP4A2 was reported to be male specific in the liver and kidneys [41] . There is a selective decrease in mRNA expression of CYP4A2 but not of either CYP4A1 or CYP4A3 in vitamin A-deficient rat's liver [27] . S.III was confirmed in our laboratory to have the ability to stimulate AhR in human hepatoma cells, HepG2, manifested by induction of CYP1A [36] . The reduction of PPARα protein expression by activation of AhR with S.III treatment of HepG2 cells (Fig. 3 and Fig. 4) suggests that the effect of AhR activation on PPARα is not only on the function but also on the expression of PPAR α. The ability of AhR stimulation with S.III to produce the same inhibitory effect on the expression of PPARα protein, even in the presence of CA (Fig. 4 C and D) indicates that the activation of PPARα with CA can not abolish the effect of AhR. The ability of AhR activation with S.III to down regulate PPARα protein in HepG2 cells suggests that AhR has an effect on PPARα expression and function in human as well as rat hepatocytes. It was reported that PPARα half-life is approximately 1 hr due to its rapid degradation by the proteasome, while ligand activation protects PPARα from ubiquitination [4] . PPARα has been shown to be in a complex with HSP90 and XAP2 in the cytoplasm [42] . At the same time, it was reported that AhR resides as a complex with HSP90 [30] and XAP2 [26] in the cytoplasm. Moreover, it was reported that exposure of different rat strains to the AhR ligand, TCDD, produced up-regulation of AhR protein expression [11] , and mRNA [12] . It could be expected that the induction of AhR protein expression by its ligand activation causes the increased AhR to compete with PPARα for the available amount of HSP90, which may affect the stability of PPARα. SRC-1 and p300, which are co-activators for PPARα [7, 48] , have also been reported to be important for AhR activation [18, 20] . It is also possible that activation of AhR causes it to compete for these co-activators with PPARα which may reduce its efficiency of binding to DNA, and renders it more sensitive to degradation. Furthermore, the down regulation of PPARα mRNA expression due to AhR activation (Fig. 6 ) could indicates that AhR activation affects PPARα at transcriptional or post-transcriptional level by affecting the stability of PPARα mRNA. In fact, TCDD was reported to decrease the PPAR gamma mRNA expression in 10T1/2 cells through activation of ERK [15] . However, the mechanism of suppression of PPARα mRNA by AhR stimulation needs further investigation. Further examination of the effect of AhR activation on the PPARα-partner, RXRα surprisingly showed that RXRα protein expression was also reduced by S.III in a dose-dependent manner (Fig. 5) . The suppression of RXRα protein by AhR stimulation could be the mechanism by which AhR activation disturbs the function of PPARα. Indeed it was found that PPARα-mediated functions were altered in RXRα-deficient mice [47] . In the senescent male Fischer-344 rats, a 30% decline of the peroxisomal-oxidation and catalase activities was coinsided with the similar decline in the hepatic expression of the RXRα protein [6] . However, there was no dramatic effect of either CA or S.III treatment on RXRα mRNA in our experiments, and therefore AhR stimulation may affect RXRα protein levels through enhancing its degradation. It was reported that di-(2-ethylhexyl) phathalate (DEHP) (a PPARα ligand) decreased the TCDD-induced hyperlipidaemia and toxicity in F344 rats [43] . We have recently found that treatment of Wistar rats with PPARα ligand down regulates AhR expression and function [36] . In the liver, muscle, and heart, activation of PPAR α increases the expression and activity of lipoprotein lipase (LPL), an enzyme involved in lipolysis [35] , while in chickens, as in mammals, the TCDD-induced body wasting is accompanied by decreased LPL activity [8] . From our present and previous results, it seems that there is a mutual inhibitory effect between AhR and PPARα function and we hypothesize that this mutual inhibitory relationship is mediated by the two receptors mainly through competition for the common pool of the co-activators and, hence, affecting the stability of the receptor proteins. Also from the results of this study we present a new piece of evidence through which an AhR ligand could affect lipid metabolism and thereby possibly predispose animals to the development of Type2 diabetes.
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